The research collaboration for Moderna will be managed by its venture company Valera, which is focused on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases.
As part of the deal, Valera will sponsor programs of preclinical and clinical research at the Institut Pasteur aimed at discovering and developing new approaches to combat known and emerging viral and bacterial diseases.
Moderna president and CEO Stephane Bancel said: "Through our partnership with the Institut Pasteur, we will work with world-class researchers and clinicians who will be critical allies as we strive to develop a transformative approach to fighting infectious diseases for patients throughout the world.
"This agreement builds on our strategy of partnering with leaders in critical fields of medicine, from AstraZeneca, Alexion, Merck and DARPA to our recently announced collaboration with the Karolinska Institutet, to advance the development of mRNA-based drugs and vaccines across multiple therapeutic areas."